NEW YORK (GenomeWeb News) — Cellectis has sub-licensed to GlaxoSmithKline patents for a process used to replace, remove, or insert genes in a genome by homologous recombination, Cellectis said Friday.
 
The company, which licensed the technology from the Pasteur Institute, said GlaxoSmithKline will use it in its drug research for in vitro and in vivo “modifications and manipulations of genetic material.”
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.